{"id":1520,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2015-04-29","marketCap":1848.53515625,"name":"Viking Therapeutics Inc","phone":"18587044660.0","outstanding":100.02999877929688,"symbol":"VKTX","website":"https://vikingtherapeutics.com/","industry":"Biotechnology"},"price":18.485,"year":2023,"month":12,"day":9,"weekday":"Saturday","title":"Impact of Regulatory Changes and Government Policies on Viking Therapeutics Inc and its Sector","date":"2023-12-09","url":"/posts/2023/12/09/VKTX","content":[{"section":"Background","text":"Viking Therapeutics Inc is a biopharmaceutical company that focuses on the development of novel therapies for metabolic and endocrine disorders. The company operates in a highly regulated industry, where regulatory changes and government policies can have a significant impact on its stock and the overall sector."},{"section":"Regulatory Changes","text":"Regulatory changes in the healthcare industry can greatly affect Viking Therapeutics Inc stock. For instance, if regulatory authorities impose stricter guidelines for drug development or approval processes, it may lead to delays in the company's pipeline and potentially impact its financial performance. On the other hand, if regulatory changes favor faster drug approvals or provide incentives for innovative drug development, it can positively impact the company's stock."},{"section":"Government Policies","text":"Government policies can also have a profound impact on Viking Therapeutics Inc and its sector. Policies related to drug pricing and reimbursements can significantly affect the company's revenue and profitability. For example, if the government introduces policies that lower drug prices or limit reimbursement rates, it may result in reduced revenue for Viking Therapeutics Inc. Conversely, policies that support higher drug prices or increase reimbursement rates can have a positive effect on the company's financials."},{"section":"Policy Implications","text":"The policy implications of regulatory changes and government policies on Viking Therapeutics Inc and its sector are twofold. Firstly, it is crucial for the company to closely monitor and adapt to any regulatory changes to ensure compliance and minimize potential disruptions in its operations. This may involve investing in additional resources or adjusting drug development strategies. Secondly, the company should actively engage with policymakers to advocate for policies that align with its business objectives and support innovation in the pharmaceutical industry."},{"section":"Conclusion","text":"In conclusion, regulatory changes and government policies have a significant impact on Viking Therapeutics Inc stock and its sector. The company needs to navigate these changes effectively to mitigate risks and maximize opportunities. Additionally, proactive engagement with policymakers can help shape policies that promote growth and sustainability in the biopharmaceutical industry."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1702041260,"headline":"Why Viking Therapeutics Was Crushing It This Week","id":124386144,"image":"https://s.yimg.com/ny/api/res/1.2/tmlP5dMQzN9ooOJ3frgspw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD01ODY-/https://media.zenfs.com/en/motleyfool.com/bf8c02466428727b90aee47d90a58db4","symbol":"VKTX","publisher":"Yahoo","summary":"A multibillion-dollar deal in the healthcare industry helped lift the stock of a company, Viking Therapeutics (NASDAQ: VKTX), not directly involved in the transaction.  As a result, according to data compiled by S\u0026P Global Market Intelligence, Viking's share price was up by a whopping 39% week to date as of Friday before market open.  The week kicked off with global pharmaceutical company Roche (OTC: RHHBY) announcing it signed an agreement essentially to acquire clinical-stage biotech Carmot Therapeutics.","url":"https://finance.yahoo.com/m/37d6ee32-db00-326d-806c-bddad8093a93/why-viking-therapeutics-was.html"},{"category":"company","date":1701944100,"headline":"Biotech Alert: Searches spiking for these stocks today","id":124364683,"image":"","symbol":"VKTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3246085759"},{"category":"company","date":1701785407,"headline":"Viking: Results From 2 Clinical Trials Of Weight Loss Drug Ahead, Other Catalysts On Tap","id":124310220,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1468999087/image_1468999087.jpg?io=getty-c-w1536","symbol":"VKTX","publisher":"SeekingAlpha","summary":"Viking has four catalysts on tap in H1'24 and has cash for years to come. Read why my analysis of VKTX stock suggests a buy rating.","url":"https://seekingalpha.com/article/4656106-viking-results-from-two-clinical-trials-of-weight-loss-drug-ahead-other-catalysts-on-tap"},{"category":"company","date":1701687540,"headline":"Viking Therapeutics rises on Roche acquiring peer Carmot","id":124279780,"image":"","symbol":"VKTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240667732"},{"category":"company","date":1701685500,"headline":"Weight-loss drug developers rise after Roche agrees to buy Carmot","id":124279739,"image":"","symbol":"VKTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240625716"},{"category":"company","date":1701675300,"headline":"RIOT, VKTX and FREY are among pre market gainers","id":124282773,"image":"","symbol":"VKTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240426805"},{"category":"company","date":1701672060,"headline":"Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), BioNTech SE (BNTX) and Viking Therapeutics (VKTX)","id":124316147,"image":"","symbol":"VKTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241328675"},{"category":"company","date":1701662820,"headline":"Viking Therapeutics Breaks Above 200-Day Moving Average - Bullish for VKTX","id":124316149,"image":"","symbol":"VKTX","publisher":"Market News Video","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241091377"},{"category":"company","date":1701656520,"headline":"Noteworthy Monday Option Activity: VKTX, SGEN, SAIA","id":124286983,"image":"","symbol":"VKTX","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240940022"},{"category":"company","date":1701638040,"headline":"Obesity Drugs Have Multi-Billion-Dollar Market Potential, Says Oppenheimer — Here Are 2 Stocks to Take Advantage","id":124274748,"image":"https://media.zenfs.com/en/tipranks_452/7e4aaba050fc340c90cab664d915f228","symbol":"VKTX","publisher":"Yahoo","summary":"A key to success in the stock market is a touch of foresight. Not quite precognition, but an ability to spot and put together clues and trends, to discern the ‘next big thing’ before it hits. This is true in every stock sector, but today we’ll focus on biotech. The biotech firms have famously high product lead times, paired with equally high overhead expenses; it’s a combination that would make them unlikely investments, except that when a drug is approved, it can turn into a blockbuster. Succes","url":"https://finance.yahoo.com/news/obesity-drugs-multi-billion-dollar-211400382.html"},{"category":"company","date":1701454320,"headline":"Health Up as Pfizer Slides -- Health Care Roundup","id":124252254,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"VKTX","publisher":"MarketWatch","summary":"Health-care companies rose, but not by as much as the broad market, after a major setback for one entrant in the race to launch an effective weight-loss...","url":"https://www.marketwatch.com/story/health-up-as-pfizer-slides-health-care-roundup-fd39573e"},{"category":"company","date":1701431640,"headline":"Pfizer hits new 52-week low after weight loss setback","id":124232532,"image":"","symbol":"VKTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3237188228"},{"category":"company","date":1701405000,"headline":"Weight-Loss Stocks Are Getting Pricey. Time to Worry About a Bubble?","id":124235670,"image":"https://images.barrons.com/im-31617813/social","symbol":"VKTX","publisher":"MarketWatch","summary":"Eli Lilly and Novo Nordisk, riding the wave of enthusiasm for obesity meds, are seeing their stock prices soar. But behind them are coming new therapies from...","url":"https://www.marketwatch.com/articles/weight-loss-drugs-eli-lilly-novo-nordisk-stocks-b867d642"},{"category":"company","date":1701400020,"headline":"Market Today: Coinbase Surges Amid Bitcoin Rally, Gold Hits Record High","id":124235556,"image":"","symbol":"VKTX","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3237437478"},{"category":"company","date":1701173842,"headline":"Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 74% of the company","id":124145815,"image":"https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","symbol":"VKTX","publisher":"Yahoo","summary":"Key Insights Significantly high institutional ownership implies Viking Therapeutics' stock price is sensitive to their...","url":"https://finance.yahoo.com/news/viking-therapeutics-inc-nasdaq-vktx-121722275.html"}]}